Key2Brain
- Biotech or pharma, therapeutic R&D
- Carve-out from a mid-size European specialty pharma – 7 years of development
- In the forefront of TfR-mediated BBB-crossing technologies
- Early pipeline of proprietary novel therapies
- Proof-of-concept established in vivo showing efficient BBB-crossing
- Three industry research collaborations
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}